UCB has entered a new multi‑project strategic alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons, aiming to accelerate the development of novel oncology candidates by ...

UCB is adding a big piece to its immunology pipeline with a multi-billion dollar deal to buy Candid Therapeutics, a clinical-stage biotech company developing therapies in a promising but competitive ...

UCB UCB-1.64%decrease; down pointing triangle said it agreed to buy Candid Therapeutics for up to $2.2 billion, in a deal that seeks to bolster the Belgian pharmaceutical company’s pipeline of ...

The acquisition draws some similarities to UCB's agreement in 2022 to purchase epilepsy drugmaker Zogenix. (UCB) After a recent streak of buyouts by some of Big Pharma's serial acquirers, Belgium's ...

G lobal biopharmaceutical giant UCB, Inc. plans to invest $2 billion in Georgia to establish its first U.S. pharmaceutical biologics manufacturing facility. The investment will generate 330 new jobs ...

UCB plans to build a $2 billion manufacturing facility near its U.S. headquarters in Atlanta, Georgia. It will become the first plant in the U.S. for the Belgium-based company and will produce ...

UCB has entered the red-hot T-cell engager (TCE) space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate. At the center of the deal is ATG-201, a CD19/CD3 ...

After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its up-and-coming immunology powerhouse. As the first med to selectively ...

Abstract: Mobile Edge Computing (MEC) is an emerging network architecture designed to enhance Quality of Service (QoS) by bringing computational resources and storage closer to end users. In MEC ...

`oops, just found the 'maxscore' didn't update, although the code has passed all the tests. update, modified score and maxScore funtions update, misunderstood the game score rule, actually the first ...